Hairy cell leukaemia+1
Not recruitingStudy of Obinutuzumab, Vemurafenib, and Cobimetinib for Hairy Cell Leukemia in Patients Previously Treated with Purine Analogs or Unfit for Chemotherapy
Study of Obinutuzumab, Vemurafenib, and Cobimetinib for Hairy Cell Leukemia in Patients Previously Treated with Purine Analogs or Unfit for Chemotherapy
- Disease:Hairy cell leukaemiaHairy cell leukaemia recurrent
- Substances:CobimetinibObinutuzumab+1
Italy- Participants:18–64 years · 65+ years
- Substances:Cobimetinib
- Sponsor:Universita Degli Studi Di Perugia








